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Inflammaging is defined as a chronic low-grade and systemic inflammation that 
accelerates the process of biological aging and is associated with many age-related diseases 
including cardiovascular disease (CVD), Rheumatoid Arthritis (RA), Myeloproliferative 
disease, Inflammatory Bowel disease, Alzheimer’s disease, and Frailty (1). There are many 
contributors to this inflammatory status including adiposity, senescent cells, and aged 
monocytes which secrete a low level of pro-inflammatory cytokines in the absence of 
antigenic challenge (2). Senescent cells are metabolically active, non-proliferative, but highly 
pro-inflammatory cells that accumulate in tissue and organs throughout the body in 
association with age-related decline in the innate immune system’s clearance capability (e.g. 
natural killer cells) (3). Aging is of course strongly associated with increased risk of CVD, 
the leading cause of worldwide mortality (4). Platelets play a vital role in normal haemostasis 
and are key players in the pathogenesis of atherothrombosis. These abundant anuclear cells 
not only directly mediate thrombosis but are now recognised as true inflammatory cells that 
can both propagate inflammatory responses and directly respond to inflammation (5). 
Antiplatelet drugs are therefore important for the prevention of thrombotic events in high risk 
patients with established CVD.  
Intrinsic platelet reactivity varies between individuals and increases with age (6, 7). In 
older individuals, platelet hyperreactivity therefore occurs more commonly and is associated 
with chronic age-related CVD, comorbidities and mortality. Furthermore, underlying platelet 
reactivity can significantly affect responsiveness to antiplatelet drugs used to prevent 
thrombosis (8-10). Although the mechanisms that govern platelet reactivity in age are 
multifactorial (e.g. genetics, poor glucose control, dyslipidemia and oxidative stress), the 
precise pathways linking inflammaging to platelet function are not yet fully defined. Despite 
this, inflammatory cytokines such as TNF-α, IL-1IL-8and IL-6 are elevated with age and 
associate with a suite of inflammatory conditions and CVD.   Inflammatory mediators can 
also modify platelet function. For example, IL-6 has been implicated in altering the 
Megakaryocytic/Platelet axis, potentially leading to polyploidization and consequent 
thrombopoiesis with a shift towards a more prothrombotic phenotype and a higher mean 
platelet volume (MPV) (11). Furthermore platelets express GP130 which can bind to 
complexes of IL-6 and soluble IL-6 receptor α (sIL-6Rα) to further prime platelets via 
transcellular signaling and further increase their reactivity during inflammation (12). The 
incidence of CVD as a comorbidity in age-related diseases is also high suggesting a common 
pathophysiology mediated by inflammatory cytokines. Acquired platelet hyperreactivity is 
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thus an important modifiable phenotype that forms an attractive therapeutic target for an 
aging population at risk of chronic diseases mediated by inflammaging.   
A recent paper by Davizon-Castillo et al in Blood now further establishes how platelet 
hyperreactivity is driven by chronic inflammation (13). An excellent commentary on this 
article by Podrez was also in the same issue (14). This research builds upon a series of studies 
from some of the authors studying altered platelet function in aging. The authors now 
demonstrate that the pro-inflammatory cytokine TNF-α drives metabolic reprogramming of 
megakaryocytes (MK), platelet mitochondrial dysfunction and platelet hyperreactivity as part 
of normal aging in humans and mice. Furthermore, exogenous administration of TNF-α to 
young mice also recapitulated the aging platelet phenotype. Older mice had increased plasma 
levels of TNF-α and increased platelet counts but with no change in leukocyte count, in 
agreement with previous studies (15, 16). Upon stimulation, washed murine platelets from 
older mice exhibited heightened ⍺IIbβ3 integrin expression, increased phosphatidylserine 
exposure and formed larger thrombi more rapidly on collagen coated slides. Interestingly it 
has been shown previously that TNF-α levels are much higher in the bone marrow 
compartment when compared to plasma in aged mice suggesting that local bone marrow 
MKs will be more susceptible to inflammaging (17).  
There is good evidence implicating monocytes as a source of both bone marrow and systemic 
increases in pro-inflammatory cytokine levels, including TNF-α (18). Furthermore, both this 
paper and other studies have shown that monocyte derived TNF-α is implicated in the 
increased platelet count, reactivity and mitochondrial mass in patients with 
myeloproliferative disease (19, 20). It is intriguing that activated platelets also avidly interact 
with and bind to monocytes, further resulting in significant upregulation of the production of 
inflammatory cytokines (21). In a related study by some of the same authors, aging platelets 
have been shown to not only exhibit altered transcriptomes but to contain a 9-fold increase  
(compared to younger adults) in levels of granzyme A, a serine protease not previously 
identified in human platelets (22). This was also shown to upregulate inflammatory cytokine 
synthesis (e.g. IL-8 and MCP-1) in monocytes via TLR-4 and caspase 1. Although TNF-α 
levels were not reported in that study, it is possible that there could be significant 
amplification of cytokine production and platelet reactivity through this pathway in aging 
(23). Changes in platelet reactivity are further supported by the increase in platelet-derived 
products measured in plasma in healthy older participants, and further increases in the context 
of arterial disease including alpha granule contents and platelet-derived microparticles (24). 
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The increase in platelet-derived microparticles may in turn accentuate the monocyte pro-
inflammatory phenotype and encourage a thrombo-inflammatory cascade effect (25). 
Aging-associated transcriptional changes in MKs were measured at the single cell level. In 
addition to identifying temporal clusters of MKs that represent maturation status, the authors 
identified key pathways that were differentially regulated with age. Metabolic pathways and 
mitochondrial dysfunction were implicated as key age-associated changes. This may align 
with the observed increase of mitochondrial mass in patients with myeloproliferative disease, 
which is associated with chronic inflammation, with TNF-α strongly implicated.  The single 
most highly upregulated transcript in older mouse MKs was class 1A aldehyde 
dehydrogenase (ALDH1A), which was also shown to be highly expressed in platelets. 
Metabolomic analysis also highlighted elevated pentose phosphate pathway intermediates. 
Increased ALDH1A and elevated pentose phosphate pathway activity is indicative of 
increased oxidative stress and is probably an attempted compensatory response to mitigate 
increased oxidative stress due to damage from free radicals and inflammation-associated 
damage. The increased reactivity of aged platelets may be due to the increased metabolic 
activity in resting aged platelets. Increased mitochondrial mass may also result in increased 
release of microparticle associated and free mitochondria upon platelet activation further 
exacerbating systemic inflammation (27). Chronic exposure to TNF-α in young mice over the 
course of 20 days also promoted a transition to the older MK transcriptome and recapitulated 
platelet hyperreactivity and the increased platelet mass observed in older mice. Strikingly the 
authors show that TNF-α- blockade in older mice over the course of 10 days could resolve 
platelet hyperreactivity and restored normal αIIbβ3 expression in response to thrombin. TNF-
α blockade reduced mitochondria mass but did not reduce platelet count. The TNF-α pathway 
was essential for the development of platelet hyperreactivity and increased mitochondrial 
mass as illustrated by the lack of effect of exogenous administration of TNF-α to TNF 
receptor deficient (p55/p75 KO) mice. Indeed bulk RNA-seq analysis confirmed that the 
MKs from old mice were transcriptionally homogeneous and to MKs from young mice 
exposed to TNF-α.  
For the first time a well-established causative link between inflammaging and platelet 
associated hyperreactivity has been demonstrated. This opens the door to further probing 
TNF-α inhibition as a possible adjunct to existing preventative measures (e.g. antiplatelet 
drugs) to further reduce thrombotic risk and CVD. Proof of concept has been shown in RA 
patients receiving anti-TNF-α therapy resulting in a reduction in inflammation and platelet 
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reactivity (28, 29).  The increased incidence of CVD associated with RA also supports the 
importance of the thrombo-inflammatory pathways outlined by Davizon-Castillo et al. 
However, long-term use of TNF-α inhibitors has been associated with an adverse safety 
profile in RA trials (30). Interestingly, the safety profile of TNF-α inhibitors increases for 
ankylosing spondylitis; these patients are typically younger and receive monotherapy so may 
be a better cohort to establish a true safety profile (30). Nevertheless, identification of this 
inflammatory pathway is an exciting advance and may lead to new therapeutics. This 
research further emphasizes the interplay between aging, platelets and monocytes that results 
in inflammaging, platelet hyperreactivity and immunothrombosis. 
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